Cigna CI

Reference table

1. The two businesses, and which one is working

Segment revenue, from seg_prod and reconciled against the filings ($M):

The June 2026 quarter, from the 8-K earnings release of 2026-07-30:

Read the segment lines and the shape of this company changes. The release states that total revenue growth was "driven by growth in both Evernorth Health Services and Cigna Healthcare" but that adjusted income "increased 6%... driven by higher contributions from Cigna Healthcare." Evernorth — 85% of revenue — grew its adjusted revenues 6% and shrank its pre-tax adjusted income from operations by 2%.

That is the single most important operating fact in this file and no field in the payload contains it. A pharmacy benefit manager whose revenue grows and whose pre-tax profit falls is either absorbing price concessions, losing mix to lower-margin business, or investing ahead of revenue. The release does not say which, and the earnings-call transcript that would is not available to this programme.

On the medical care ratio, the company offers an explanation and we report it at half weight. The 130-basis-point increase to 84.5% is attributed "primarily [to] higher prior year risk adjustment benefits within our Individual and Family Plans business recognized in second quarter 2025" — that is, an unusually favourable item in the comparison base rather than deterioration now. Supporting that: favourable prior-year reserve development was $268 million in the six months to June 2026 against $297 million a year earlier — similar, not collapsing. Against it: the full-year guided range is 83.7% to 84.7%, and 84.5% is near the top of it.

Guidance, and it was raised. The 2026-07-30 release states the "2026 outlook for adjusted income from operations increased to at least $30.45 per share", from "at least $30.35" reaffirmed in a Regulation FD 8-K on 2026-05-13, which itself came from the 2026-04-30 release. Segment guidance: Cigna Healthcare adjusted income from operations pre-tax "at least $4,550" million, raised $25 million; Cigna Healthcare medical care ratio 83.7% to 84.7%. Note that the consensus epsAvg for FY2026 of $30.473 sits essentially at the guidance floor of "at least $30.45" — so the sell side has embedded no beat against a guidance the company has raised twice.

2. The buyback, and why it decides the verdict

From the 2026-07-30 earnings release:

> "Year to date through July 29, 2026, the company repurchased 0.9 million shares of common stock for approximately $250 million."

Against the payload's own record:

Annualised, $250 million over roughly seven months is about $430 million a year, against $3,621 million last year and $7,034 million the year before — a reduction of roughly 88% to 94% depending on the comparison. It is 0.6% of a $72.4 billion market capitalisation.

Three readings, and we cannot distinguish them from this archive. Capital may be committed elsewhere — the release states the outlook "includes the impact of expected future share repurchases", so more is planned but unquantified. Cash may be constrained by working capital in a business where net medical costs payable rose 13.4% year on year. Or management may not think the stock is cheap at nine times earnings.

What can be said without speculation is this. Cigna generated $8,389 million of free cash flow in FY2025 on a market capitalisation of $72,396 million — an 11.6% yield — and in the seven months to 29 July 2026 it returned approximately $250 million of that through buyback and roughly $940 million through dividends. A company that can retire 11% of its equity a year from free cash flow, at nine times earnings, and chooses to retire 0.6%, has made a capital-allocation decision that the filings do not explain.

This is the reason the verdict is Watch rather than Buy — Tactical. In the same batch, this house issued a Buy on a name where the treasury and four insiders were all buying. The symmetrical discipline requires that the withdrawal of the best-informed buyer count against the arithmetic here, and it does. The upgrade condition is written as a number: a buyback restarting above $1 billion a quarter.

3. Balance sheet and cash flow

Filing-verified at 2026-06-30 ($M):

Goodwill and intangibles of $73,484 million against shareholders' equity of $41,713 million means tangible common equity is approximately MINUS $31.8 billion, which is km_ttm.tangibleAssetValueTTM of MINUS $29,555 million to within rounding. This is the arithmetic legacy of the $67 billion Express Scripts acquisition of 2018 and it is not a solvency issue for a business that generates $8.4 billion of free cash flow — but it means every book-based ratio in the payload is void and none appears in this dive.

Cash flow:

Free cash flow has declined for two consecutive years — $10,240M, $8,957M, $8,389M — an 18% cumulative fall while revenue rose 41%. That is worth stating alongside the 11.6% yield, because a yield computed on a declining numerator is not the same asset as one computed on a rising one. Capital expenditure of $1,212M is 0.44% of revenue, which is what a business that owns pharmacies and software rather than factories spends; capexToDepreciationTTM of 0.427 is low but plausible given $2,775M of depreciation and amortisation that includes acquired-intangible amortisation from Express Scripts.

Capital returned in FY2025 was $5,232M — 62% of free cash flow. The 2026 run rate is closer to $1.9 billion, 23%.

4. Valuation — priced in or room?

At $273.98 (market cap $72.40B, 264.2M shares implied):

Estimate coverage is reasonable on the near years and the FY2026 consensus sits at the guidance floor. 13 analysts on FY2026 EPS and 15 on FY2027 — the anchor — with an FY2027 range of $32.547 to $33.972, a 4.4% spread, the narrowest in this batch after Colgate's. 10 on FY2028 and 4 on FY2029, the latter excluded.

Two observations on the estimate block itself. The FY2026 consensus of $30.473 is 0.08% above the company's raised guidance of "at least $30.45" — so the sell side has priced in no beat at all against a company that has beaten five times running and raised guidance twice. And the FY2026 growth rate of 2.7% is the second-lowest forward year in this batch, recovering to 9.9% and 11.0% thereafter — the same trough-then-recovery shape found on Boston Scientific, and the same unresolvable question about whether it is a trough or a waypoint.

est.ebitdaAvg and est.ebitAvg are fabricated and rejected — the twelfth consecutive file. In every one of the eight years present, ebitdaAvg is exactly 5.1825% of revenueAvg and ebitAvg is exactly 4.2508%. All forward valuation uses epsAvg, which verifies: the FY2025 epsAvg of $29.660 sits within 0.3% of the four quarterly adjusted actuals.

Enterprise value — verified clean on net debt, with the usual small NCI omission. enterpriseValueTTM of $97,976.6M less market capitalisation is exactly $25,580M, which is the 2026-06-30 balance sheet to the dollar: short-term debt $2,792M plus long-term debt $29,086M less cash $6,298M. The vendor uses the most recent quarter, financial debt only, and does not inflate it with leases. It omits the $161M of noncontrolling interests. Rebuilt: $98,138M, 0.16% above the vendor's figure — the second-cleanest enterprise-value construction in this batch after Boston Scientific's.

4a. What today's price assumes (the inversion)

At $273.98 — 9.0x FY2026 consensus adjusted EPS and 8.2x FY2027 — the price embeds:

• Adjusted EPS of at least $30.45 in FY2026. (Company guidance, raised 2026-07-30; consensus $30.473.) The first half delivered $15.57 ($7.79 plus $7.78), leaving $14.88 — a modest sequential decline that the September consensus of $7.50 is consistent with. This is the least demanding assumption in the price.
• Adjusted EPS of $33.500 in FY2027, up 9.9%. (Consensus, 15 analysts.) On revenue growth of 4.3%, that needs margin expansion — from a group whose largest segment's pre-tax adjusted income is currently declining 2%. This is the most fragile assumption in the price.
• Evernorth's pre-tax profit stops falling. (Our derivation; the release supplies the MINUS 2%.) Evernorth is 85% of revenue. If its pre-tax adjusted income declines at 2% a year, Cigna Healthcare has to grow roughly 12% a year for the group to hit the FY2027 consensus — and Cigna Healthcare's medical care ratio is rising.
• The market keeps paying 8-9x forward earnings. (Our number.) Cigna traded in the low-to-mid teens for most of the decade to 2024. At 7.5x FY2027E the stock is $251; at 11x it is $369. The band is wide because the multiple, not the estimate, carries the risk.
• Pharmacy benefit reform does not materially change Evernorth's economics. (Our derivation; the knowledge base supplies the counter-argument.) Four independent channels argue otherwise, one of them stating that separating formularies from PBMs "would collapse their rent-extraction model." None is a legislative forecast and none names Cigna; all describe 85% of its revenue.

4b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+9.9%, from FY2026E $30.473 to FY2027E $33.500) + multiple drift (modest EXPANSION, from 8.2x to roughly 9.2x, +12%) + shareholder yield (+2.6% — a 2.24% dividend plus roughly 0.35% of buyback at the current pace).

Our base assumes a modest re-rating and we should be honest that this is a judgement rather than a mechanism. At 8.2x forward earnings with an 11.6% free-cash-flow yield, Cigna is priced as an impaired business. If Evernorth's profit merely stops falling, that pricing is too harsh; if the pharmacy benefit model is genuinely being disintermediated, it is not harsh enough.

Note what the return does NOT contain, and this is the change from prior years. In FY2024 the buyback alone was $7,034 million — 9.7% of today's market capitalisation. At the 2026 pace it is 0.35%. A large part of the return that Cigna shareholders earned in 2022 and 2024 was share-count reduction, and it has been withdrawn. Weighted average diluted shares fell from 313.1M (FY2022) to 265.9M (FY2025) — a 15.1% reduction in three years — and were 263.96M in the June 2026 quarter, down only 1.5% from the 268.15M of a year earlier.

4c. Variant perception (where we differ, what would surprise)

• We are 9.2% below the street and the gap is entirely the multiple. Consensus is $339.23, which is 10.1x FY2027E; our base is 9.2x. We use the same consensus rows. We also note that the lowest of 39 published targets is $302 — 10.2% above the current price — and there is not one sell rating, which is the third occurrence of that pattern in this batch and which we treat as a caution.
• We think the buyback collapse is the most under-discussed fact about this company and it is disclosed in one sentence of a press release. From $7,034M in FY2024 to approximately $250M in seven months of 2026, at nine times earnings, with an 11.6% free-cash-flow yield. No analyst target in this file is expressed in terms of it, and the payload does not contain it. Watchable number: buyback spend disclosed in the 2026-10-29 release.
• We think the knowledge base's discarded lane deserves more weight than its zero conviction score implies, and we say so explicitly rather than burying it in a footnote. Four independent channels — all_in, eli_lilly_ceo, biotech_hangout (twice) — argue between August 2025 and January 2026 that pharmacy benefit managers face reform, antitrust risk or obsolescence. Not one names Cigna, so under the entity discipline not one enters the score. All describe the business that generates 85% of Cigna's revenue and whose pre-tax profit is already declining 2%. This is the most on-thesis discard this programme has produced and it is an explicit input to the Watch designation.
• Positive surprise that would force a re-rate: Evernorth pre-tax adjusted income returning to growth; or a buyback restarting above $1 billion a quarter; or FY2027 consensus revised up from $33.500; or the medical care ratio coming in below 84% for the full year.
• Negative surprise that would break the thesis: Evernorth pre-tax income declining more than 5%; or federal legislation on 100% rebate pass-through or formulary separation advancing to a floor vote; or the medical care ratio exceeding the 84.7% guidance ceiling; or a goodwill impairment against the $44,924 million balance.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $33.500, low $32.547, high $33.972, 15 analysts), cross-checked against free cash flow.

• Bear ~$228 — 7.0x the FY2027 consensus LOW of $32.547. Cross-checks: 7.5x FY2026E; a 3.7% free-cash-flow-implied dividend cover on an unchanged $6.14 payout; 6.7% below the 52-week low of $244.41; 24.5% below the street's low target of $302. The scenario: Evernorth's pre-tax income keeps declining, pharmacy benefit reform advances, the medical care ratio breaches 84.7%, FY2027 consensus is cut toward $30, and a business priced as impaired is confirmed as one. MINUS 16.8%.
• Base ~$308 — 9.2x the FY2027 consensus MEAN of $33.500. Cross-checks: 10.1x FY2026E; 8.3x FY2028E; an enterprise value of $107.0bn against FY2027 revenue of $299.0bn; a free-cash-flow yield of 10.3% on FY2025's $8,389M at that price. Sensitivity, stated openly: 7.5x gives $251 — 8.4% BELOW spot — and 11x gives $369. The estimate has a 4.4% spread and the multiple assumption has a 47% one, so the multiple is doing essentially all the work. The scenario: Evernorth stabilises, the medical care ratio stays inside guidance, consensus is met, the buyback partially resumes, and the multiple recovers about one turn. +12.4%.
• Bull ~$395 — 11.6x the FY2027 consensus HIGH of $33.972. Cross-checks: 10.6x FY2028E; 27.0% above the 52-week high of $311.00; 16.4% above the street's $339.23 and 1.3% below the street high of $400. The scenario: Evernorth's profit reaccelerates, PBM reform stalls, the buyback returns to $5-7 billion a year and retires 8% of the equity, and managed care re-rates from the trough multiples the sector currently carries. +44.2%.

Base is 12.4% above spot; asymmetry roughly 2.63:1 (16.8% down, 44.2% up), before a shareholder yield of approximately 2.6%. On arithmetic alone that is close to the Buy — Tactical threshold, and Section 8 sets out the three specific reasons it stops short.

5. Knowledge base — one inverted-stance claim and the most on-thesis discard in this programme

Raw hits: 27. After a case-sensitive entity test: 1. Name-level claims on Cigna: 1, stance-tagged bullish and unfavourable on content. Discarded: 26 — and the discard is more informative than the survivor.

The sweep ran entity terms CI, Cigna, The Cigna Group and Evernorth plus free text on cigna, evernorth, pharmacy benefit, pbm and express scripts across all 52,021 distilled claims.

The one entity match, verbatim:

> 2025-07-12 · stance tagged BULLISH · conviction 80 · horizon: thesis · entities: UnitedHealth Group, CVS Health, Cigna, Elevance, Humana · channel: business_breakdowns · no named speaker · skill 1.0 · categories: managed care, vertical integration

> "UNH out-earns peers on integration depth; CVS is retail-heavy, Elevance late, Humana over-concentrated in Medicare Advantage — none match Optum's synergy."

This is the documented inverted-stance defect and it has to be graded on content. The stance tag reads bullish, and the claim is indeed bullish — about UnitedHealth. Toward the other four named entities it is comparative and unfavourable: CVS is "retail-heavy", Elevance is "late", Humana is "over-concentrated", and "none match Optum's synergy." Cigna is named in the entity list and receives no individual criticism, which means the claim's only statement about Cigna is that it does not match the competitor's integration economics. We grade it as mildly NEGATIVE for Cigna, and a naive conviction score reading the stance tag would have recorded a bullish 80 on this name.

The discard, and it is the most thematically relevant discard this programme has produced. Twenty-six text-only hits, every one about pharmacy benefit managers, and Evernorth is a pharmacy benefit manager producing 85% of Cigna's revenue. The strongest, verbatim:

> 2025-09-09 · BEARISH · conviction 75 · all_in · entities: UnitedHealth, PBMs, big health insurers — "Vertically-integrated insurers/PBMs game an opaque system and face antitrust risk; separating formularies from PBMs would collapse their rent-extraction model."

> 2025-09-29 · BEARISH · conviction 65 · eli_lilly_ceo · categories: PBM, healthcare — "PBMs are at the end of their S-curve—original IT/bulk-negotiation rationale is obsolete and service has 'enshittified' toward their own benefit; transparent PBMs rising."

> 2025-08-26 · bullish · conviction 55 · biotech_hangout · categories: PBM reform, drug pricing — "Increasing likelihood of real PBM/middlemen reform this year; strong White House sense that middlemen harm patients and the system."

> 2026-01-23 · bullish · conviction 50 · horizon: fact · biotech_hangout · categories: PBM reform, drug pricing, policy — "PBM reform gaining momentum (transparency, 100% rebate pass-through) could benefit biotech innovation, though not yet locked in."

> 2025-11-11 · bullish · conviction 65 · eli_lilly_ceo · entities: Eli Lilly — "LillyDirect sells directly to consumers online, upending the traditional middleman/PBM distribution model."

> 2025-09-09 · bullish · conviction 70 · all_in · entities: Cost Plus Drugs — "Transparent 15% cost-plus drug pricing is defensible even if PBMs are dismantled, run lean and AI-driven with only ~70 employees."

Three disciplines applied, and they all point the same way. First, the entity test: not one of these twenty-six names Cigna or Evernorth, so not one enters the conviction score. Second, the channel discipline: the eli_lilly_ceo claims carry the documented store defect of hosting other companies' claims, and they are management-voice framing from a pharmaceutical manufacturer with a direct commercial interest in weakening pharmacy benefit managers — half weight, and a conflict worth naming. Third, none of these is a legislative forecast; the most concrete, from 2026-01-23, explicitly says reform is "not yet locked in."

And yet. Four independent channels, across six months, arguing that the category producing 85% of Cigna's revenue faces reform, antitrust action or disintermediation — with zero claims arguing the opposite — is a genuine, one-directional, multi-sourced overlay on this specific company's economics. It enters no score and it is an explicit input to the Watch designation, in the same way the consumer-credit lane was on Capital One. The nearest thing to a rebuttal in the store is business_breakdowns, 2025-07-12, bullish 82: "Optum, long overlooked, is the underappreciated profit driver and future growth engine; a $100B revenue business that would be Fortune 50 standalone" — which is an argument that vertically integrated health services are valuable, made about a competitor.

Attribution note. All 27 hits carry speaker: null except one — biotech_hangout 2026-07-17, speaker John Maraganore, role independent — and that one is about Eli Lilly rather than about pharmacy benefit managers as a category. No claim carries a management speaker_role, though the eli_lilly_ceo channel is management-voice by construction and is treated as such.

Conclusion. Breadth 1, claim count 1, net conviction negative-low. The knowledge base has one claim naming Cigna, its stance tag is inverted relative to its content, and on content it is mildly unfavourable. Behind it sits the most on-thesis discarded lane in this programme, running one direction, against 85% of the company's revenue.

6. Data integrity — what we rejected and why

Seven findings, including the worst insider block in this batch and one of the two cleanest enterprise-value constructions.

1. The insider block is unusable — every row has an EMPTY transaction type and six of eight are between one and seven years old. All eight rows belong to a single person, Bryan Holgerson, typed only as "officer: See Remarks". Every row has transactionType: "" and acquisitionOrDisposition: "". Two are dated 2026-07-01 with 0 shares at $0. The other six are dated 2019-03-01, 2020-02-27, 2021-02-26, 2022-03-01, 2023-03-01 and 2024-03-01 — the oldest is more than seven years before this dive — and each shows securitiesOwned: 0 after the transaction. There is no usable insider datum for this company: no chief executive, no chief financial officer, no director, no transaction type, and no transaction inside the last twelve months. This is the worst insider block in this batch and the only one that supports no analysis at all. Section 7 reports the absence rather than working around it.

2. inc_q carries two corrupt cells in the June 2026 row — partial-row corruption. The vendor reports Q2 2026 grossProfit of $14,965M against $6,470M in the March 2026 quarter and $7,886M in the June 2025 quarter — a 2.3x jump with no corresponding revenue or cost movement (revenue rose 4.6% sequentially). And depreciationAndAmortization for the same row is ZERO, against $650M, $580M and $682M in the three adjacent quarters. Every other field in the row is sound: revenue $71,668M matches the release's $71.7bn, operating income $2,676M is consistent, net income $1,660M matches the release's $1.7bn, and diluted EPS of $6.29 matches exactly. Two fields wrong and six right in one quarter is the partial-row class, and each field must be checked individually.

3. seg_prod has no eliminations line for FY2025 or FY2024, so the segments exceed revenue by $7,413M. Evernorth $234,953M plus Cigna Healthcare $47,412M is $282,365M against total revenues of $274,952M. The FY2023 and earlier rows DO carry a "Corporate and Eliminations" line, so the block lost a field rather than never having had one. The segment values themselves are consistent with the filings; the block simply does not reconcile.

4. seg_geo reports only a United States line for its most recent year, and that year is FY2024 — there is no FY2025 entry at all. The FY2024 row contains "UNITED STATES": $241,563M and nothing else, against total FY2024 revenue of $247,121M. FY2023 and earlier rows carry an "All Other Countries" line; FY2024 does not. So the most recent geography available is two years stale and is missing its international component. This is the ninth consecutive batch in which seg_geo has failed on at least one name, and Cigna is the fourth failure in this batch.

5. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. Exactly 5.1825% and 4.2508% of revenueAvg in all eight years present. All forward valuation uses epsAvg.

6. bal_a.totalDebt excludes the finance lease line rather than including it, which is the opposite of the usual defect. The vendor reports FY2025 shortTermDebt $592M plus longTermDebt $30,871M equalling totalDebt of $31,463M — and separately reports capitalLeaseObligations of $68M which is NOT added. Both the short-term and long-term figures match the 10-Q's comparative column exactly ($592M and $30,871M). In a batch where five names had operating leases wrongly added to debt, Cigna's totalDebt is arithmetically consistent with the filed balance sheet, and the $68M omission is immaterial. Recorded as correct.

7. Every book-value-based ratio is void. tangibleBookValuePerShareTTM is MINUS $111.97 and km_ttm.tangibleAssetValueTTM is MINUS $29,555M, because goodwill of $44,924M plus intangibles of $28,560M exceeds shareholders' equity of $41,713M by roughly $31.8 billion. These are correct outputs applied to a balance sheet carrying the residue of a $67 billion acquisition, and priceToBookRatioTTM of 1.697x, returnOnEquityTTM of 15.2% and grahamNumberTTM of $297.16 are all rejected as lenses for this name.

VERIFIED CLEAN — recorded because a clean check is a finding.

enterpriseValueTTM is right, current and lease-free. The $25,580M residual over market capitalisation reconciles exactly to the 2026-06-30 balance sheet — short-term debt $2,792M plus long-term debt $29,086M less cash $6,298M — using the most recent quarter and without adding leases. The only defect is the omission of $161M of noncontrolling interests, which takes the rebuilt figure to $98,138M, 0.16% higher. This is the second-cleanest enterprise-value construction in this batch.

capitalExpenditure and the free-cash-flow chain are internally consistent at $1,212M / $1,406M / $1,573M with operating cash flow of $9,601M / $10,363M / $11,813M, producing free cash flow of $8,389M / $8,957M / $10,240M and a recomputed 11.59% yield against the vendor's freeCashFlowYieldTTM of 12.59% (the difference being the trailing-twelve-month window). capexToDepreciationTTM of 0.427 is low but plausible for an asset-light intermediary whose depreciation includes Express Scripts intangible amortisation.

The share count reconciles. Market capitalisation ÷ price implies 264.24 million shares against 263.96 million diluted in the June quarter — a 0.1% difference consistent with the small buyback.

Non-equity tripwire — checked and passed. CI is common stock, NYSE-listed. Price of $273.98 is not par-like; beta is 0.303; volume was 2.04M shares (~$559M of turnover); the 52-week band of $244.41 to $311.00 is a 27% range — the narrowest in this batch after Colgate's, consistent with the low beta. This is common equity.

Vendor composite rating — noted, not used. The rating block gives A- / 4 overall with 5 of 5 on discounted cash flow and 1 of 5 on debt-to-equity. The discounted-cash-flow sub-score rests on the free-cash-flow chain, which is sound; the debt-to-equity sub-score is computed against a book equity dominated by $73.5 billion of goodwill and intangibles and carries no weight.

7. Technicals and insiders

• Price $273.98. MINUS 11.9% from the 52-week high of $311.00; +12.1% above the 52-week low of $244.41. Position within the annual range: 44th percentile.
• Below both moving averages: MINUS 4.3% below a 50-day average of $286.30; MINUS 2.1% below a 200-day average of $279.73, with the 50-day above the 200-day. The short-term trend has rolled over inside an intact longer-term one.
• RSI 35.2 — the most oversold reading in this batch and the mirror image of Boston Scientific's 82.0 in the same file. MACD MINUS 1.17.
• Current distance from the six-year peak: MINUS 25.3%, against MINUS 11.9% from the 252-day high. The two differ, so the six-year peak sits outside the last twelve months — the field working correctly, not a defect.
• Relative performance is flat-to-behind across every window: 3-month MINUS 1.9% against SPY +7.6%; 6-month +0.9% against SPY +11.1%; 12-month +4.5% against SPY +24.3% and QQQ +30.8% — a 20-point twelve-month deficit accumulated with almost no volatility, which is what a beta of 0.303 produces.
• Sentiment: 1 strong buy, 28 buy, 10 hold, ZERO sells across 39 analysts. Consensus target $339.23 (+23.8%), median $340, high $400 (+46.0%), low $302 — 10.2% ABOVE spot. The lowest of thirty-nine published targets is more than ten per cent above the current price and there is not one sell rating, which is the third occurrence of that pattern in this batch. We treat unanimity about the absence of downside as a caution rather than a comfort.

Today's move and the entry

CI closed 2026-08-04 at $273.98, DOWN 2.86% or $8.08 from $282.06 — the largest single-day decline in this batch. It opened at $276.00, traded $272.08 to $276.98, and closed in the lower half of the range on 2.04M shares. No company-specific filing is dated 2026-08-04; the last event was the 2026-07-30 earnings release, five days earlier, which beat consensus and raised guidance.

A 2.9% fall five days after a beat-and-raise, in a stock with a beta of 0.303, is unusual and this file cannot explain it. No 8-K, 10-Q or insider filing is dated within the window. What can be said is that the entry is the opposite of Boston Scientific's in the same batch: RSI 35.2, below both moving averages, down on the day, on a name that has just raised guidance. If the arithmetic supported a Buy, this would be a good day to act on it. The reason it does not is in Section 8, and it is not the chart.

Insiders — nothing usable, and the absence is the finding

The insider block contains eight rows and not one is analysable. All eight belong to Bryan Holgerson, typed "officer: See Remarks". Every row carries an empty transactionType and an empty acquisitionOrDisposition. Two, dated 2026-07-01, report 0 shares at $0. The remaining six are dated 2019-03-01, 2020-02-27, 2021-02-26, 2022-03-01, 2023-03-01 and 2024-03-01 — a pattern of one annual event, most likely a vesting, at prices from $183.44 to $294.61, each showing securitiesOwned: 0 afterwards.

There is no transaction by the chief executive, the chief financial officer or any director anywhere in the file, and no transaction of any kind within the last thirteen months that carries a type.

We report that as an absence rather than as an absence of buying or selling, because the block is structurally broken and cannot distinguish the two. In a dive whose verdict turns on what the company's own capital allocation says about the price, having no insider data at all is a material gap and it is stated as one.

The company-level datum stands in for it and is documented in Section 2: repurchases of approximately $250 million year to date through 2026-07-29, against $3,621 million in FY2025 and $7,034 million in FY2024.

8. Verdict, kill-criteria and flip conditions

Watch.

The arithmetic gets close to a Buy and three specific things stop it.

The arithmetic first, because it is genuinely attractive. At $273.98 Cigna trades at 9.0x the FY2026 consensus of $30.473 — which is the company's own raised guidance floor — and 8.2x FY2027's $33.500. Free cash flow of $8,389 million in FY2025 is an 11.6% yield. The dividend is 2.24%. The company has beaten adjusted earnings in all five quarters in the file and raised full-year guidance twice, most recently five days ago. Of 39 analysts, none says sell and the lowest target of $302 is 10.2% above the price. Our base of $308 is 12.4% above spot with 2.63:1 asymmetry, and RSI at 35.2 is the most oversold entry in this batch.

What stops it, in three specifics.

First, and decisively: the company has stopped buying its own stock. $7,034 million in FY2024, $3,621 million in FY2025, and approximately $250 million in the seven months to 2026-07-29 — a reduction of roughly 93%, at nine times earnings, by a business generating an 11.6% free-cash-flow yield. The filings do not explain it. In this same batch, this house issued a Buy on Boston Scientific partly because its treasury and four insiders were buying. The symmetrical discipline requires that the withdrawal of the best-informed buyer count against Cigna, and it does.

Second, the larger segment's profit is falling. Evernorth Health Services is 85% of revenue and its pre-tax adjusted income from operations DECLINED 2% in the June quarter on adjusted revenues up 6%. The group's growth came, in the company's own words, "driven by higher contributions from Cigna Healthcare" — the 15% segment, whose medical care ratio rose 130 basis points to 84.5% against a guided ceiling of 84.7%. Consensus needs FY2027 adjusted EPS growth of 9.9% from a group where 85% of revenue is producing less profit than it did a year ago.

Third, the knowledge base's discarded lane is aimed at exactly that segment. Four independent channels between August 2025 and January 2026 argue that pharmacy benefit managers face reform, antitrust risk or disintermediation, with zero claims arguing the other way. None names Cigna and none enters the conviction score. All describe 85% of its revenue. And the one claim that does name Cigna is stance-tagged bullish while its content places Cigna among the peers that "none match Optum's synergy."

Why not Hold. Because the base case is 12.4% above spot with 2.63:1 asymmetry at an oversold entry, and because there are two specific, dated, watchable events that would resolve the objection. A name whose central question resolves at the next print belongs on a watchlist, not in the dead file.

Why not Buy — Tactical. Because a business at eight times earnings whose largest segment is shrinking in profit, whose model faces a one-directional expert lane, and whose own board has cut the buyback 93% is not a price signal we are willing to front-run.

Pre-registered UPGRADE conditions — what would take this to Buy — Tactical:

• Evernorth pre-tax adjusted income from operations returning to growth, from MINUS 2%. This is the single most important number in the file.
• The buyback restarting above $1 billion a quarter, which would say the board thinks the stock is cheap at these levels.
• The Cigna Healthcare medical care ratio coming in below 84% for the full year, against a guided 83.7% to 84.7% and 84.5% in the June quarter.
• A price below roughly $250, which on the base of $308 restores a payoff ratio above 3:1 — and is 2.3% above the 52-week low.
• FY2027 consensus adjusted EPS revised UP from $33.500.
• Any usable insider datum at all — the current block contains none.

Pre-registered KILL criteria — what would take this to Avoid:

• Evernorth pre-tax adjusted income declining more than 5% in any quarter.
• Federal legislation on 100% rebate pass-through or formulary separation advancing to a floor vote, which would convert the knowledge base's discarded lane into a priced event.
• The medical care ratio exceeding the guided 84.7% ceiling.
• FY2026 guidance cut below the "at least $30.45" now committed.
• A goodwill impairment against the $44,924 million balance, which would confirm that the Express Scripts economics have permanently changed.
• Free cash flow falling below $7 billion, from $10,240M, $8,957M and $8,389M across three years — a series already down 18% while revenue rose 41%.

Where CI fits in the Synthos Framework Portfolio. The healthcare sleeve, on the watchlist at zero weight, with a 2% starter contingent on either a price below $250 or Evernorth pre-tax income returning to growth. Sizing note: with a beta of 0.303 and a 2.24% dividend, any eventual position here is a defensive income holding rather than a growth one, and should be judged on the free-cash-flow yield rather than the earnings multiple. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $273.98, with the fair-value anchors, the kill criteria and the upgrade conditions all gradeable.

Single biggest risk: pharmacy benefit manager reform. Evernorth Health Services generated $234,953 million of FY2025 revenue — 85% of the group — and its pre-tax adjusted income from operations is already declining 2% year on year. The knowledge base's discarded lane, which enters no score and is reported because it is one-directional and dead-centre on this business, contains all_in at conviction 75 stating that "separating formularies from PBMs would collapse their rent-extraction model", eli_lilly_ceo at 65 stating that "PBMs are at the end of their S-curve", and two biotech_hangout claims describing reform momentum on transparency and 100% rebate pass-through. None of that is a legislative forecast — the most concrete explicitly says reform is "not yet locked in" — and the pharmaceutical-manufacturer voice among them has a direct commercial interest in the outcome. The offsetting consideration is real and it is why this is Watch rather than Avoid: Cigna serves over 180 million customer relationships, generates $8.4 billion of annual free cash flow, trades at eight times forward earnings, and has beaten and raised guidance in the face of all of this. A business priced for impairment that is not impaired is a good investment. A business priced for impairment that is being impaired is a value trap. The two numbers that distinguish them — Evernorth's pre-tax income and the buyback — are both disclosed quarterly, and the next disclosure is 2026-10-29.

Provenance & disclosures

• Traceability: 1 knowledge-base claim names Cigna out of 52,021 distilled claims, and its stance tag is inverted relative to its content (raw hits 27, surviving a case-sensitive entity test 1, name-level 1, discarded 26; breadth 1, net conviction negative-low). The claim: business_breakdowns, 2025-07-12, stance tagged bullish, conviction 80, skill 1.0, speaker: null, entities UnitedHealth Group, CVS Health, Cigna, Elevance and Humana — "UNH out-earns peers on integration depth; CVS is retail-heavy, Elevance late, Humana over-concentrated in Medicare Advantage — none match Optum's synergy." The claim is bullish about UnitedHealth and comparatively unfavourable to the four other named entities including Cigna; we grade it on content as mildly NEGATIVE, and record that a naive score reading the stance tag would have logged a bullish 80 on this name. The 26 discarded text-only hits are the most on-thesis discard this programme has produced, because Evernorth is a pharmacy benefit manager producing 85% of Cigna's revenue and every one of them is about pharmacy benefit managers: all_in 2025-09-09 (bearish 75, "Vertically-integrated insurers/PBMs game an opaque system and face antitrust risk; separating formularies from PBMs would collapse their rent-extraction model"), eli_lilly_ceo 2025-09-29 (bearish 65, "PBMs are at the end of their S-curve"), biotech_hangout 2025-08-26 ("Increasing likelihood of real PBM/middlemen reform this year"), biotech_hangout 2026-01-23 ("PBM reform gaining momentum... though not yet locked in"), eli_lilly_ceo 2025-11-11 (LillyDirect "upending the traditional middleman/PBM distribution model") and all_in 2025-09-09 (Cost Plus Drugs, "defensible even if PBMs are dismantled"). Not one names Cigna or Evernorth, so not one enters the conviction score; the eli_lilly_ceo claims additionally carry the documented channel defect of hosting other companies' claims and are management-voice framing from a manufacturer with a direct commercial interest in weakening pharmacy benefit managers, at half weight. Four independent channels running one direction across six months, against the segment producing 85% of revenue and already showing declining pre-tax profit, is an explicit input to the Watch designation even at zero conviction weight. All quotes are verbatim from the stored claim text.
• Data as-of: fundamentals — balance sheet, debt, segment commentary, medical care ratio, guidance and the buyback disclosure through 2026-06-30, filing-verified from the 10-Q filed 2026-07-30 and the 8-K earnings release filed the same day; annual figures for FY2025, FY2024 and FY2023 from the 10-K filed 2026-02-26 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873598 = 2026-08-04T19:59:58Z ($273.98, MINUS 2.86%; 50-DMA $286.30; 200-DMA $279.73; RSI 35.2; MACD MINUS 1.17; beta 0.303) · knowledge-base claims 2026-08-04. Cigna's fiscal year is the calendar year. All figures come from the Synthos vendor data file for CI or from the SEC filings in the CI archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-26 (fiscal 2025); 10-Q filed 2026-04-30 (March 2026 quarter); 10-Q filed 2026-07-30 (June 2026 quarter — the source of the balance sheet, the debt figures and the 42.8% debt-to-capitalisation ratio); 8-K filed 2026-04-30 (first-quarter earnings release); 8-K filed 2026-05-13, a Regulation FD disclosure reaffirming full-year 2026 adjusted income from operations of "at least $30.35 per share"; 8-K filed 2026-07-30, carrying the complete second-quarter earnings release — the source of the Evernorth pre-tax adjusted income decline of 2%, the 84.5% medical care ratio, the raised "at least $30.45" outlook, the segment guidance, and the disclosure that "year to date through July 29, 2026, the company repurchased 0.9 million shares of common stock for approximately $250 million." All carry preserved [TABLE] statement data where applicable.
• Where the filings contradicted or corrected the vendor (detailed in Section 6): the insider block, in which all eight rows belong to one officer, every row carries an empty transaction type and an empty acquisition/disposition flag, two report zero shares at zero price, and six are dated between 2019-03-01 and 2024-03-01 — the worst insider block in this batch and the only one supporting no analysis whatever; inc_q, whose June 2026 row reports grossProfit of $14,965M against $6,470M and $7,886M in adjacent quarters and depreciationAndAmortization of ZERO against $650M, $580M and $682M, while every other field in the same row (revenue, operating income, net income, diluted EPS) matches the filing — the partial-row class; seg_prod, which lost its "Corporate and Eliminations" line after FY2023 and whose FY2025 segments therefore exceed total revenue by $7,413M; seg_geo, whose most recent entry is FY2024, contains only a United States line of $241,563M against $247,121M of revenue, and has lost the "All Other Countries" line that FY2023 and earlier rows carry; est.ebitdaAvg/ebitAvg, fabricated at exactly 5.1825% and 4.2508% of revenue in all eight years; and every book-value-based ratio, void because $73,484M of goodwill and intangibles exceeds $41,713M of shareholders' equity, producing a tangible book value per share of MINUS $111.97. Above all, the buyback collapse from $7,034M (FY2024) and $3,621M (FY2025) to approximately $250M year to date is disclosed in one sentence of a press release and appears in no vendor field. Where vendor and filing AGREED — recorded, because a clean check is a finding: enterpriseValueTTM's $25,580M residual reconciles EXACTLY to the 2026-06-30 balance sheet — short-term debt $2,792M plus long-term debt $29,086M less cash $6,298M — using the most recent quarter and without adding leases, with the only defect being the omission of $161M of noncontrolling interests (rebuilt $98,138M, 0.16% higher), making it the second-cleanest enterprise value in this batch; bal_a.totalDebt of $31,463M is arithmetically consistent with the filed balance sheet ($592M plus $30,871M, both matching the 10-Q comparative column exactly), with capitalLeaseObligations of $68M correctly NOT added — the opposite of the lease-inflation defect that fired on five other names in this batch; the capital-expenditure and free-cash-flow chain is internally consistent at $1,212M / $1,406M / $1,573M against operating cash flow of $9,601M / $10,363M / $11,813M; and the share count reconciles, with 264.24 million implied by market capitalisation ÷ price against 263.96 million diluted in the June quarter.
• Basis note: analyst estimates are on adjusted income from operations per share, which the 8-K defines as "shareholders' net income... excluding net investment gains/losses, amortization of acquired intangible assets and special items" plus the group's share of certain joint-venture investment results. The June quarter bridges GAAP diluted EPS of $6.29 to adjusted $7.78 — a $1.49, 23.7% adjustment dominated by acquired-intangible amortisation from the Express Scripts transaction. earn_cal's epsActual series is the adjusted figure and matches the release exactly. Trailing adjusted EPS of $31.48 (8.7x) is built from the four quarterly releases; trailing GAAP EPS of $24.31 (11.3x) is reported alongside. est.ebitdaAvg and est.ebitAvg are rejected outright; all forward valuation uses epsAvg, which verifies to within 0.3% against FY2025 actuals. Note that the FY2026 consensus of $30.473 sits 0.08% above the company's raised guidance of "at least $30.45", so the sell side has embedded no beat against a company that has beaten five consecutive quarters.
• Estimate coverage: 13 analysts on FY2026 adjusted EPS and 15 on FY2027 — the anchor for all three fair values, with an FY2027 range of $32.547 to $33.972, a 4.4% spread — falling to 10 on FY2028 and 4 on FY2029, which is excluded. Revenue coverage is thinner than EPS coverage at 9, 12 and 14 analysts across FY2026 to FY2028, which is unusual and is noted.
• Peer note: the vendor peer set — Becton Dickinson, Cardinal Health, Centene, Cencora, CVS Health, Elevance, Humana, IDEXX Laboratories, Regeneron, Zoetis — contains four genuine managed-care or pharmacy-services comparables (Centene, Cencora, CVS Health, Elevance) plus Humana, and five that are not: a medical-device maker, a diagnostics company, a biotechnology company and two animal-health businesses. UnitedHealth Group — the company the knowledge base's one entity-matched claim uses as the benchmark against which Cigna is found wanting, and the only true scale comparable for a combined insurer-and-PBM — is ABSENT. No peer-multiple comparison is drawn.
• Fair-value caveat: the $228 / $308 / $395 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 7.0x the low of $32.547, 9.2x the mean of $33.500, and 11.6x the high of $33.972 — cross-checked against free cash flow and enterprise value. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 7.5x gives $251, which is 8.4% BELOW spot, and 11x gives $369. Because the earnings estimate has a 4.4% spread and the multiple assumption has a 47% one, the multiple is doing essentially all the work in the fair-value range, and the base case requires modest multiple expansion from 8.2x to 9.2x — that is a judgement about whether a business priced for impairment is impaired, not a mechanism, and it is named as such in Section 4b.
• Guidance and management-framing note: the full-year 2026 outlook of "at least $30.45 per share", the Cigna Healthcare segment target of "at least $4,550" million pre-tax, the medical care ratio range of 83.7% to 84.7%, and the attribution of the 130-basis-point medical care ratio increase to "higher prior year risk adjustment benefits within our Individual and Family Plans business recognized in second quarter 2025" are management statements from the July 2026 earnings release, half-weighted under the standing house rule. The reviewed figures — revenues, shareholders' net income, the balance sheet, the debt-to-capitalisation ratio and the year-to-date repurchase amount — are not.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.